GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medexus Pharmaceuticals Inc (TSX:MDP) » Definitions » Change In Receivables

Medexus Pharmaceuticals (TSX:MDP) Change In Receivables : C$-2.5 Mil (TTM As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Medexus Pharmaceuticals Change In Receivables?

Medexus Pharmaceuticals's change in receivables for the quarter that ended in Dec. 2023 was C$0.6 Mil. It means Medexus Pharmaceuticals's Accounts Receivable declined by C$0.6 Mil from Sep. 2023 to Dec. 2023 .

Medexus Pharmaceuticals's change in receivables for the fiscal year that ended in Mar. 2023 was C$-11.3 Mil. It means Medexus Pharmaceuticals's Accounts Receivable increased by C$11.3 Mil from Mar. 2022 to Mar. 2023 .

Medexus Pharmaceuticals's Accounts Receivable for the quarter that ended in Dec. 2023 was C$29.8 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Medexus Pharmaceuticals's Days Sales Outstanding for the three months ended in Dec. 2023 was 80.45.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Medexus Pharmaceuticals's liquidation value for the three months ended in Dec. 2023 was C$-123.7 Mil.


Medexus Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Medexus Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medexus Pharmaceuticals Change In Receivables Chart

Medexus Pharmaceuticals Annual Data
Trend Dec13 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.55 -10.80 -4.41 5.61 -11.27

Medexus Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.48 -2.84 -4.61 4.33 0.65

Medexus Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medexus Pharmaceuticals  (TSX:MDP) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Medexus Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=29.82/33.823*91
=80.45

2. In Ben Graham's calculation of liquidation value, Medexus Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Medexus Pharmaceuticals's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=11.019-175.501+0.75 * 29.82+0.5 * 36.842
=-123.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medexus Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Medexus Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Medexus Pharmaceuticals (TSX:MDP) Business Description

Traded in Other Exchanges
Address
35 Nixon Road, Suite 1, Bolton, ON, CAN, L7E 1K1
Medexus Pharmaceuticals Inc is an innovative and rare disease pharmaceutical company with a strong North American commercial platform and a portfolio of proven best-in-class products. The company's focus is on the therapeutic areas of hematology, auto-immune diseases, and allergy.
Executives
Benoit Gravel Director